Thursday, March 14, 2013
Researchers at the University of California, San Diego and Ventrix Inc.
have developed a catheter-compatible hydrogel that restored cardiac function in
a pig model with myocardial infarction.1 Ventrix is now scaling up
manufacture of the hydrogel, called VentriGel,
and hopes to take it into clinical trials by year end.
Progressing into patients
Lou, K.-J. SciBX 6(10); doi:10.1038/scibx.2013.232
Published online March 14, 2013
S.B. et al. Sci. Transl. Med.; published online
Feb. 20, 2013; doi:10.1126/scitranslmed.3005503
Contact: Karen L. Christman, University of California, San Diego, La
J.M. et al. Biomaterials 30, 5409-5416 (2009)
J.M. et al. J. Am. Coll. Cardiol. 59, 751-763 (2012)
AND INSTITUTIONS MENTIONED
Covidien plc (NYSE:COV), Dublin, Ireland
C.R. Bard Inc. (NYSE:BCR), Murray Hill, N.J.
Harvard Medical School, Boston, Mass.
Kinetic Concepts Inc. (NYSE:KCI), San Antonio, Texas
Massachusetts General Hospital, Boston, Mass.
Mississippi State University, Mississippi State, Miss.
University of California, San Diego, La Jolla, Calif.
Ventrix Inc., San Diego, Calif.